Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-17
2010-06-08
Wilson, James O (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07732616
ABSTRACT:
Disclosed are compounds of the Formulas I and Vand pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 4851535 (1989-07-01), Todo et al.
patent: 5231094 (1993-07-01), Bru-Magniez et al.
patent: 5525625 (1996-06-01), Bridges et al.
patent: 6310060 (2001-10-01), Barrett et al.
patent: 6440966 (2002-08-01), Barrett et al.
patent: 6469004 (2002-10-01), Barrett et al.
patent: 6506798 (2003-01-01), Barrett et al.
patent: 6642215 (2003-11-01), Madsen et al.
patent: 6821963 (2004-11-01), Barrett et al.
patent: 6835749 (2004-12-01), Tecle
patent: 7067532 (2006-06-01), Boyle et al.
patent: 7211572 (2007-05-01), Miyazaki e
patent: 7425637 (2008-09-01), Wallace et al.
patent: 2003/0004193 (2003-01-01), Barret et al.
patent: 2003/0092748 (2003-05-01), Barrett et al.
patent: 2003/0195183 (2003-10-01), Zhilov
patent: 2003/0216460 (2003-11-01), Wallace et al.
patent: 2003/0232869 (2003-12-01), Wallace et al.
patent: 2004/0116710 (2004-06-01), Wallace et al.
patent: 2005/0026964 (2005-02-01), Black et al.
patent: 1373314 (1974-11-01), None
patent: WO 95/03286 (1995-02-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 00/40235 (2000-07-01), None
patent: WO 00/40237 (2000-07-01), None
patent: WO 00/41505 (2000-07-01), None
patent: WO 00/42029 (2000-07-01), None
patent: WO 00/68201 (2000-11-01), None
patent: WO 01/05390 (2001-01-01), None
patent: WO 01/05391 (2001-01-01), None
patent: WO 01/05392 (2001-01-01), None
patent: WO 01/05393 (2001-01-01), None
patent: WO 01/68619 (2001-09-01), None
patent: WO 02/06213 (2002-01-01), None
patent: WO 02/18319 (2002-03-01), None
patent: WO03/076405 (2003-09-01), None
patent: WO 03/077855 (2003-09-01), None
patent: WO 03/077914 (2003-09-01), None
patent: WO 2005/000818 (2005-01-01), None
patent: WO2005/000818 (2005-01-01), None
patent: WO2005/123692 (2005-12-01), None
Patani, et al. Chem. Rev., 96, 1996, pp. 3147-3176.
Lima, et al. Current Med. Chem., 12, 2005, pp. 23-49.
M-C- Viaud, et al. “Acylation of Oxazolo[4,5-b]pyridin-2(3H)-ones, 2-Phenyloxazolo[4,5-b] pyridines and Pyrrolo[2,3-b]pyridin-2(2H)-ones”; Tetrahedron; 1997, pp. 5159-5168; vol. 53, No. 14; Elsevier Science Ltd.
Moreau, et al. “Synthesis and Anticonvulsant Properties of Triazolo- and Imidazopyridazinyl Carboxamides and Carboxylic Acids”; Bioorganic & Medicinial Chemistry; 1998; pp. 983-991; vol. 6; Elsevier Science Ltd.
Bachman “Further Studies of Aminobenzacrfidines”; Journal of Organic Chemistry; 1948; pp. 89-96; vol. 13.
Konykhova, N.A. et al., “Unusual Reaction of Enhydrazines With Oxalyl Chloride”, Chemistry of Heterocyclic Compounds, 2001, 647-648, 37(5), New York, NY, USA.
Schober, Bernt D. et al., “Pyridazines With Heteroatom Substituents in Positions 3 and 5. 6. SN Reactions in Position 5 of 2-aryl-5-hydroxypyridazin-3(2H)-ones”, Journal of Heterocyclic Chemistry, 1990, 471-477, 27(3).
European Search Report corresponding to European Patent Application No. 04811727.9-1211, dated Dec. 12, 2006.
Gotthardt et al., “Synthesis and Physical Properties of First 3,3-bridged Bis- and Tris(1,3-thiazolium-4-olates) as well as one 5,5-Bridged Bis-(1,3-thiazolium-4-olate) and its Conversion into 3,3-(1,4-pheylene)BisA2(1ETA)- pyridononeU”, Chemische Berichte, Verlag Chemie GMBH, 1987, 1017-1022, 120(b), Weinheim Germany.
Potts et al., “Mesoionic Compounds, XXXII Cycloaddition Reactions of the Anhydro-4-Hydroxythiazolium Hydroxide System with Olefinic Dipolarophiles”, Journal of Organic Chemistry; 1974; pp. 3631-3640 39(25).
Potts et al., “Mesoionic Compounds, XXXI Preparation and Cycloaddition Reactions of the Anhydro-4- Hydroxythiazolium Hydroxide System with Acetylenic Dipolarophiles”, Journal of Organic Chemistry, 1974 pp. 3627-3630 39(25).
Ried, et al.“Reactions with Cyclobutenediones. XXIX. Structure and reactions of Phenylcyclobutenedione-Enamine 1:1 Addition Compounds”, Justus Liebigs Annalen Der Chemie, 1972, 1-12, 762.
Ried, et al., “Reactions of Cyclobutenediones. XX Synthesis and Reactivity of p-Substituted Phenylcyclobutenediones”, Chemische Berichte, 1971, 2622-2628, 104(8).
Gotthardt et al., “Synthesis and Physical Properties of First 3,3-bridged Bis- and Tris(1,3-thiazolium-4-olates) as well as one 5,5-Bridged Bis-(1,3-thiazolium-4-olate) and its Conversion into 3,3-(1,4-pheylene)BisA2(1ETA)- pyridonone”, Chemische Berichte, Verlag Chemie GmbH, 1987, 1017-1022, 120(b), Weinheim Germany.
Potts et al., “Mesoionic Compounds, XXXI Preparation and Cycloaddition Reactions of the Anhydro-4- Hydroxythiazolium Hydroxide System with Acetylenic Dipolarophiles”, Journal of Organic Chemistry, 1974 pp. 3627-3630 39(25).
Potts et al., “Mesoionic Compounds, XXXII Cycloaddition Reactions of the Anhydro-4-Hydroxythiazolium Hydroxide System with Olefinic Dipolarophiles”, Journal of Organic Chemistry; 1974; pp. 3631-3640 39(25).
Ried, et al.“Reactions with Cyclobutenediones. XXIX Structure and reactions of Phenylcyclobutenedione-Enamine 1:1 Addition Compounds”, Justus Liebigs Annalen Der Chemie, 1972, 1-12, 762.
Ried, et al., “Reactions of Cyclobutenediones. XX Synthesis and Reactivity of p-Substituted Phenylcyclobutenediones”, Chemische Berichte, 1971, 2622-2628, 104(8).
Sebolt-Leopold, et al., “Blocade of the MAP Kinase Pathway Suppresses Growth of Colon Tumors in vivo”, Nature Medicine, vol. 5, No. 7, Jul. 1999, 810-816.
U.S. Appl. No. 10/992,612, Restriction Requirement dated Sep. 9, 2007.
U.S. Appl. No. 10/992,612, Non-Final Office Action Dated Jan. 23, 2008.
U.S. Appl. No. 10/992,612, Final Office Action Dated Aug. 7, 2008.
U.S. Appl. No. 10/992,612, Notice of Allowance Dated Nov. 20, 2008.
U.S. Appl. No. 11/132,164, Restriction Requirement Dated Aug. 23, 2007.
U.S. Appl. No. 11/132,164, Non-Final Office Action Dated Jan. 4, 2008.
U.S. Appl. No. 11/132,164, Notice Allowance Dated May 30, 2008.
Blake James
Lyssikatos Joseph P.
Marlow Allison L.
Seo Jeongbeob
Wallace Eli M.
Array BioPharma Inc.
Hogan & Hartson LLP
Moore John R.
Willis Douglas M
Wilson James O
LandOfFree
Dihydropyridine and dihydropyridazine derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dihydropyridine and dihydropyridazine derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dihydropyridine and dihydropyridazine derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4233883